MorphoSys sells research and diagnostic segment for 53M euros; California startup Allakos raises $32M; Promedior completes move to MA;

Conversations on Twitter :

 @FierceBiotech: Baxter joins Big Pharma funds on $38M B round for Naurex antidepression R&D. Article | Follow @FierceBiotech

@JohnCFierce: Troubled Intercell (bought Iomai) throws in the towel, signs off on merger deal with Vivalis. More | Follow @JohnCFierce

@RyanMFierce: Dang. Another biotech deal this busy am. Naurex nails down $38M B round led by Baxter for depression candidate. Release | Follow @RyanMFierce

> Germany's MorphoSys AG has agreed to sell its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories for €53 million in cash. The biotech plans to focus on its own antibody pipeline work. Release

> San Mateo, CA-based startup Allakos Therapeutics rounded up $32 million in its Series A round. Novo Ventures led the round with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund. The biotech is developing antibodies for allergic and inflammatory diseases. Release

> Promedior has completed its relocation from Philadelphia to the Boston area with the official opening of its lab and office space in Lexington, MA. Story

> Flexion Therapeutics says that FX006, its intra-articular, sustained-release steroid, maintained therapeutic concentrations in the knee joint significantly longer than the most commonly prescribed immediate-release steroid, triamcinolone acetonide, in a Phase II pharmacokinetic study. Release

Pharma News

@FiercePharma: AstraZeneca beats back would-be Crestor copycats. Report | Follow @FiercePharma

> France herds patients, pharmacists toward cheap generics. News

> Teva taps S. Korea's Handok for assault on $14B market. Story

> U.S. branded sales to end 2012 with 3.5% decline. Article

Medical Device News

 @FierceMedDev: Malaysia is working hard to diversify its med device manufacturing base. International competition is increasing. News | Follow @FierceMedDev

@MarkHFierce: Barron's sees J&J poised for major growth, but NOT through its med device business. More | Follow @MarkHFierce

 @DamianFierce: Quintiles is handling recruitment and "clinical services" for AstraZeneca's novel depression drug. Story | Follow @DamianFierce

> Orthofix resolves Medicare kickback case. News

> Amarantus licenses Alzheimer's blood Dx. Story

> Bioresorbable stents hit India, but most patients can't afford them. Article

Biotech IT News

> How lessons from iPhone's Siri aid biological exploration. Story

> GlaxoSmithKline dials up Vodafone for mobile tech alliance. Article

> Russian billionaire backs 23andMe in $50M round. News

> Could computers predict the next big Alzheimer's drug? Report

CRO News

> Patheon closes $255M Banner deal. Item

> Charles River projects a modest 2013, slides on the Street. Story

> Catalent inks biosimilar deal with Japanese CMO. Article

> Quintiles recruiting for AstraZeneca's novel depression drug. News

> Warnex closes bioanalytics sale, exits CRO biz. Report

And Finally… A group of researchers at Plymouth University Peninsula Schools of Medicine and Dentistry says that a commonly used cognitive test used in Alzheimer's drug research is deeply flawed, skewing the results of drug trials in the field. Release


Suggested Articles

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.

The new parliamentary arithmetic gives Boris Johnson the numbers to pass the withdrawal agreement and take the U.K. out of the EU.